Éric Durot

机构：Centre Hospitalier Universitaire de Reims, Hôpital Robert-Debré, Université de Reims Champagne-Ardenne · ORCID：0000-0003-3463-0089

发表论文 133 篇 · 总被引 1105 次 · h-index 18

代表论文

• Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia (2024 · Journal of Clinical Oncology · 被引 33)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 28)
• Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) (2024 · Journal of Clinical Oncology · 被引 16)
• Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment (2025 · Blood · 被引 15)
• Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines (2025 · European Journal of Cancer · 被引 12)
• The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network (2024 · Leukemia · 被引 9)